1. Scrip
  2. >>New Products

BMS Grows Its Lung Cancer Portfolio With ‘Best-In-Class’ Augtyro Approval

Drug Addresses 1%-2% Of NSCLC Patients

 
• By Mandy Jackson

Bristol Myers Squibb won US FDA approval for Augtyro (repotrectinib), from its $4.1bn Turning Point acquisition last year, in the treatment of ROS1-positive non-small cell lung cancer (NSCLC).

Lungs anatomy part glowing light X-ray abstract concept vector illustration
ROS1-positive NSCLC patients tend to be younger and women • Source: Shutterstock

Bristol Myers Squibb Company already is a dominant player in the non-small cell lung cancer (NSCLC) market with its PD-1 inhibitor Opdivo (nivolumab) and CTLA4 inhibitor Yervoy (ipilimumab), but the big pharma continues to build up its presence in the space. The US Food and Drug Administration approved Bristol’s ROS1/NTKK inhibitor Augtyro (repotrectinib) on 15 November for adults with locally advanced or metastatic ROS1-positive NSCLC, including both treatment-naïve and treatment-experienced patients.

Key Takeaways
  • BMS won US FDA approval for Augtyro (repotrectinib) as a treatment for ROS1-positive NSCLC in first-line and treatment-experienced patients. 
  • The company believes it has a best-in-class drug, acquired in its $4.1bn Turning Point acquisition last year, that could generate $500m-$1bn in peak sales

BMS acquired Augtyro in the $4.1bn purchase of Turning Point Therapeutics Inc. last year, betting that repotrectinib’s best-in-class clinical trial results would help the company grow its revenue beyond the loss of exclusivity for Opdivo and other blockbuster products later in this decade

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

Pipeline Watch: Five Approvals And One Phase III Readout

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Merck KGaA Seals SpringWorks Buy

 
• By Kevin Grogan

The German group is paying $3.9bn to get hold of the US firm and its two approved products.

More from Scrip

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: AstraZeneca CEO cautions Europe; Pfizer CEO optimistic on US tariffs, pricing; Merck & Co reassures on pipeline; Merck KGaA buys SpringWorks; and Akeso explains ivonescimab overall survival data.

Vertex Sinks On Below-Consensus Revenue, Limited Sales From New Launches

 
• By Mandy Jackson

Vertex is in need of diversification, but in addition to its lower-than-expected Q1 revenue, sales of the company’s newest CF drug Alyftrek and pain medicine Journavx disappointed.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.